Search Within

Alexander Paul Boardman

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (3)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Department of Medicine (7)
  3. GME, Medicine (7)
  4. Graduate Medical Education (7)
  5. Hematologic Malignancies, Division of (7)
  6. Hematology-Oncology Fellows (7)

More Groups

People
  1. Gilles Salles (7)
  2. Heiko Schoder (7)
  3. Maria Palomba (7)
  4. Joachim Yahalom (5)
  5. Alison Moskowitz (4)
  6. Andrew Intlekofer (4)

More People

Years
  1. 2025 (2)
  2. 2024 (4)
  3. 2023 (1)
Publications
  1. Blood (2)
  2. Blood Advances (1)
  3. Blood Cancer Journal (1)
  4. Clinical Cancer Research (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (3)
  2. American Association for Cancer Research (1)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Inc. (1)
  5. Nature Publishing Group (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improvement in radiomic features following bridging therapy is prognostic for CD19 chimeric antigen receptor (CAR) T-cell therapy outcome
    Meeting Abstract

    Hubbeling, H. G.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G. L.; Fregonese, B.; Bedmutha, A.; Boardman, A.; Dahi, P. B.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B-cell lymphoma
    Journal Article

    Hubbeling, H.; Leithner, D.; Silverman, E. A.; Flynn, J.; Devlin, S.; Shah, G.; Fregonese, B.; Wills, B.; Bedmutha, A.; Alarcon Tomas, A.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save